Skip to content

Released Oct 30, 2024, after the close

10-Q filed Nov 6, 2024, 37 days after period end · 0000950170-24-122473

Q3 2024 · 10-Q
Revenue$22.09M−12.9% vs Q3 2023−1.8% vs Q2 2024
Net Income-$26.94MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.07N/M vs Q3 2023N/M vs Q2 2024
Gross Profit$12,126,000+8.7%
Operating Income-$26,699,000N/M
Operating Cash Flowderived-$27,869,000N/M
Free Cash Flowderived-$30,124,000N/M
Margins · derived
Gross margin54.9%+10.9 pt vs Q3 2023
Operating margin-120.9%−37.4 pt vs Q3 2023
Net margin-122.0%−39.2 pt vs Q3 2023

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Revenue$22.09M$25.37M$25.65M$28.50M
Net Income-$26.94M-$21.00M-$29.43M-$13.84M
EPS Diluted-$0.07-$0.27-$0.37-$0.18

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR